Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)

BACKGROUND: Vacation can present a major problem to patients with rheumatoid arthritis (RA) treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore, the replacement of four SC doses of abatacept by a single dose of intravenous (IV) abatacept may present an accept...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Ruediger B., Gengenbacher, Michael, Richter, Symi, Dudler, Jean, Möller, Burkhard, von Kempis, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831114/
https://www.ncbi.nlm.nih.gov/pubmed/27074795
http://dx.doi.org/10.1186/s13075-016-0985-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831114/
https://www.ncbi.nlm.nih.gov/pubmed/27074795
http://dx.doi.org/10.1186/s13075-016-0985-2

Ejemplares similares